Quick answerHold and clarify
oral lefamulin with pimozide and prolonged QT.
Why this is correctChanging the tablet form or adding a dose does not remove the pharmacokinetic and electrophysiologic risk. The interacting regimen requires prescriber and pharmacist review before administration.
Easy analogy or mental pictureBuild a medication-safety chain: identify the changing cue, connect it to the labeled toxicity or interaction, interrupt preventable exposure, stabilize the client, and verify a measurable response.
Memory hookDrug, trend, urgent cue, protective action, and reassessment endpoint.NCLEX decision ruleChoose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrongOptions that continue a suspect exposure, normalize a labeled danger cue, or delay escalation leave the client at risk.
References
1DailyMed: XENLETA (lefamulin)QT prolongation, contraindicated oral coadministration with QT-prolonging sensitive CYP3A4 substrates, and ECG/electrolyte risk review